Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab

NCT04173325 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT04173325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04173325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab
Lead sponsor
Augusta University
Phase
Phase 1
Overall status
Terminated
Start date
January 6, 2020
Completion date
May 26, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma, small-cell lung cancer